Advances in Hyperkalemia Management: Implications for Patients and Providers
- CME / AMA PRA Category 1 Credit™
- MOC / ABIM MOC Part 2 Credit
PROGRAM OVERVIEW
Conventional treatment of hyperkalemia is restricted by adverse events, as well as a dearth of evidence supporting clinical use (specifically with sodium polystyrene sulfonate). For medication-induced hyperkalemia, treatment involves a dose decrease or discontinuation of the offending agent (usually a renin-angiotensin-aldosterone system inhibitor [RAASI]); however, this often prevents patients from receiving appropriate guideline-directed management. Recent research has led to the development of two novel potassium binders with good safety profiles that allow patients to maintain or increase the use of RAASIs for cardio- and reno-protection.
This CME activity, Advances in Hyperkalemia Management: Implications for Patients and Providers, will help participating clinicians identify those patient populations most likely to present with or develop hyperkalemia, and utilize the appropriate conventional and/or novel agents to correct subacute hyperkalemia.
AGENDA
Welcome and Introductions
Understanding the Current Subacute/Chronic Hyperkalemia Armamentarium
Improving the Care of Adults with and at Risk for Hyperkalemia
Q&A Session and Activity Roundup
TARGET AUDIENCE
This activity is intended for physicians, hospitalists, nephrologists, and cardiologists involved in the management and education of adults with or at risk for hyperkalemia.
EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to:
- Compare and contrast safety and efficacy data on novel and conventional agents for correcting subacute/chronic hyperkalemia
- Identify patient populations likely to present with or develop hyperkalemia
- Incorporate novel agents for correcting subacute hyperkalemia into patient care plans
ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedChi, The Maryland State Medical Society, and Rockpointe. MedChi is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
MedChi designates this online web-based activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email fberry@medchi.org.
ABIM MOC DESIGNATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through MedChi’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
FACULTY

Professor and Chairman
Department of Medicine
University of Mississippi
Jackson, MS
He completed residency training at Yale University, cardiology and advanced heart failure and transplant fellowships at Vanderbilt University, and a cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He completed his Master of Public Health degree from Harvard University and Master in Business Administration from Emory University.
Dr. Butler is board certified in advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award from the American College of Cardiology as well as the Time, Feeling, and Focus Award from the American Heart Association.
Dr. Butler has authored more than 550 peer-reviewed publications. He serves on the editorial board of several peer-reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.

Professor of Internal Medicine
Distinguished Teaching Professor
University of Texas Southwestern Medical Center
Dallas, TX
He has received numerous teaching awards, including the Regents Outstanding Teaching Award from the University of Texas and the Parkland Memorial Hospital Internal Medicine Housestaff Outstanding Teacher Award. He is a member of the Southwestern Academy of Teachers and the University of Texas Kenneth I. Shine Academy of Health Science Education. He is designated as a Distinguished Teaching Professor by the University.
DISCLOSURE
All persons in a position to control the content of a continuing medical education program provided by MedChi are required to disclose any relevant financial relationships with any commercial interest to MedChi as well as to learners. All conflicts of interest are identified and resolved by MedChi in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
FACULTY DISCLOSURES
Biff Palmer, MD: Nothing to disclose
Javed Butler, MD, MPH, MBA: Consultant/Independent Contractor: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, LinaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sanofi, V-Wave Limited, Vifor
NON-FACULTY CONTENT CONTRIBUTORS
Nicolle Rochino, PharmD, RPh; Blair St. Amand; Frank C. Berry; Steven F. Crawford, MD: Nothing to disclose
FDA DISCLOSURE
SYSTEM REQUIREMENTS
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
PROVIDER
Jointly provided by MedChi and Rockpointe
SUPPORTER
This program is supported by an unrestricted educational grant from AstraZeneca.
RELATED COURSES


FIGHTING THE UPHILL BATTLE: Current Evidence in Obesity Management
Credits 1.00 (60 min)
Format Webcourse

Improving Outcomes for Patients with Severe Hypercholesterolemia
Credits 1.00 (60 min)
Format Webcourse
Aug